Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06908473CT.gov Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cerebrovascular Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tongmai Jiangtang (this asset) | Guangdong Provincial Hospital of Traditional Chinese Medicine | P3 | B · 60 |
| Warfarin | Seoul National University Hospital | P4 | BBB |
| Aspirin | Peking Union Medical College Hospital | P3 | BB |
| Cilostazol | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Sichuan Provincial People's Hospital | P4 | BB |
| Clopidogrel | Peking Union Medical College Hospital | P3 | BB |
| Tenecteplase | University of Melbourne | P3 | BB |
| Tirofiban | Peking Union Medical College Hospital | P3 | BB |
| 3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN | University of Edinburgh | P3 | B |
+26 more in the Cerebrovascular Disorder cohort
Other indications for Tongmai Jiangtang
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Abdominal Obesity-Metabolic Syndrome | — | P3 | CCC · 54 |
| Chronic Kidney Disease | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tongmai Jiangtang in Cerebrovascular Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tongmai-jiangtang-cerebrovascular-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →